title: Efficacy and safety of recombinant human tumor necrosis factor application for the treatment of malignant pleural effusion caused by lung cancer.
abstract: Malignant pleural effusion (MPE) signifies a poor prognosis for patients with lung cancer. For treating physicians, the primary goals are to achieve sufficient control of MPE and minimize invasive intervention. Recombinant human mutant tumor necrosis factor-alpha (rhu-TNF) has been used in the treatment of MPE. The aim of our research was to evaluate the efficacy and safety of rhu-TNF application via ultrasound-guided chest tube for the treatment of MPE. rhu-TNF was administered as a single dose to 102 patients with MPE caused by lung cancer, and dexamethasone (Dxm, 5 mg) was administered 30 minutes before rhu-TNF in 35 randomly selected patients in order test its ability to prevent side effects. The primary endpoint was the efficacy of the rhu-TNF treatment (disease response rate) and side effects (pain, fever, and flu-like symptoms), evaluated four weeks after instillation. The disease response rate of rhu-TNF treatment was 81.37%. Side effects included 13 (12.75%) patients complaining of flu-like symptoms, 15 (14.71%) with fever/chill, and 14 (13.73%) with chest pain. A significantly higher efficacy was observed for treatment with 3 MU versus 2 MU of rhu-TNF (P = 0.036), while the adverse effects were similar. There was no significant association between the dose of rhu-TNF and progression-free survival (P = 0.752). In conclusion, our study shows that intra-pleural instillation of rhu-TNF achieves sufficient control of MPE and minimizes invasive intervention.
authors.affiliation: Department of Respiratory and Critical Care Medicine Jinling Hospital School of Medicine Nanjing University Nanjing China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Li
authors.affiliation: Department of Respiratory and Critical Care Medicine Jinling Hospital School of Medicine Nanjing University Nanjing China.
authors.forename: Wenkui
authors.initials: W
authors.lastname: Sun
authors.affiliation: Department of Respiratory and Critical Care Medicine Jinling Hospital School of Medicine Nanjing University Nanjing China.
authors.forename: Dongmei
authors.initials: D
authors.lastname: Yuan
authors.affiliation: Department of Respiratory and Critical Care Medicine Jinling Hospital School of Medicine Nanjing University Nanjing China.
authors.forename: Tangfeng
authors.initials: T
authors.lastname: Lv
authors.affiliation: Department of Respiratory and Critical Care Medicine Jinling Hospital School of Medicine Nanjing University Nanjing China.
authors.forename: Jie
authors.initials: J
authors.lastname: Yin
authors.affiliation: Department of Respiratory and Critical Care Medicine Jinling Hospital School of Medicine Nanjing University Nanjing China.
authors.forename: Ehong
authors.initials: E
authors.lastname: Cao
authors.affiliation: Department of Respiratory and Critical Care Medicine Jinling Hospital School of Medicine Nanjing University Nanjing China.
authors.forename: Xinwu
authors.initials: X
authors.lastname: Xiao
authors.affiliation: Department of Respiratory and Critical Care Medicine Jinling Hospital School of Medicine Nanjing University Nanjing China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Song
keywords: Intra‐pleural instillation; lung cancer; malignant pleural effusion; rhu‐TNF
references.citation: Respirology. 2001 Sep;6(3):181-5
references.pmid: 11555375
references.citation: Med Microbiol Immunol. 1999 Aug;188(1):9-14
references.pmid: 10691088
references.citation: Lung. 2013 Apr;191(2):165-75
references.pmid: 23315213
references.citation: Br J Cancer. 2006 Sep 18;95(6):717-21
references.pmid: 16940982
references.citation: Biochem Biophys Res Commun. 2014 Oct 3;452(4):1046-53
references.pmid: 25242740
references.citation: Chest. 2001 Mar;119(3):801-6
references.pmid: 11243960
references.citation: Anticancer Res. 1998 Sep-Oct;18(5D):3917-25
references.pmid: 9854504
references.citation: Anticancer Res. 2000 Nov-Dec;20(6A):4087-96
references.pmid: 11131677
references.citation: Oncologist. 2006 Apr;11(4):397-408
references.pmid: 16614236
references.citation: J Clin Oncol. 2004 Apr 1;22(7):1228-33
references.pmid: 15051770
references.citation: Cancer Immunol Immunother. 1989;29(2):144-50
references.pmid: 2720707
references.citation: Eur J Cancer. 1997 Feb;33(2):226-31
references.pmid: 9135493
references.citation: J Biol Chem. 1999 May 7;274(19):13451-5
references.pmid: 10224110